Nuvectis Pharma is a pre-revenue clinical-stage biopharmaceutical company with a balance sheet composed almost entirely of cash. As of March 31, 2026, total assets were $25.4 million, of which $25.1 million was cash and cash equivalents, with the remaining $0.3 million in other current assets. There are no PP&E, inventory, AR, or intangibles on the balance sheet. Under liquidation lens, the asset-side recovery is effectively the cash balance at 100%, yielding approximately $25.1 million in recoverable asset value. The liability stack totals $11.2 million, all current: accounts payable of $4.7 million, employee-related liabilities of $6.4 million (likely accrued compensation and severance exposure), and accrued liabilities of $36 thousand. At face value, liabilities of $11.2 million against $25.1 million in cash produces a positive residual of approximately $13.9 million, consistent with the MFFAIS CLV/LLV/OLV figure of $13.95 million. Equity per books is $14.2 million, with accumulated deficit of $105.7 million. The near-equivalence of book equity and liquidation recovery reflects the cash-dominant balance sheet: there are no haircut-sensitive assets and no long-term debt. The company has no long-term leases (office is month-to-month on a one-year renewal), no pension, and no long-term debt. Contingent milestone obligations under the NXP900 University of Edinburgh license (up to $324.6 million in pre-approval and commercial milestones plus tiered royalties) are not on-balance-sheet and are contingent; they would not crystallize in a wind-up absent reaching specified development or commercial triggers. However, a 2.5% fundraising fee obligation to UoE on future capital raises up to a cumulative $3.0 million total could create a modest current liability in a fundraising scenario. This fee structure is disclosed in MD&A but is not separately tagged in XBRL. The burn rate is the primary recovery risk: Q1 2026 operating cash outflow was $6.5 million versus $4.2 million in Q1 2025, a 56% increase year-over-year. At the current burn rate, the $25.1 million cash balance implies approximately 3.9 quarters of runway from period end before reaching zero, absent further capital raises. The company filed a $150 million shelf registration in February 2026 and has a $60 million ATM facility, but drew only $7 thousand through the ATM in Q1 2026. Liquidity runway is the primary driver of whether the positive liquidation residual persists.
▼ Community Notes